Home » Stocks » VRPX

Virpax Pharmaceuticals, Inc. (VRPX)

Stock Price: $3.85 USD -0.10 (-2.53%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.95 +0.10 (2.60%) May 13, 7:39 PM
Market Cap 17.36M
Revenue (ttm) n/a
Net Income (ttm) -4.34M
Shares Out 4.51M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.85
Previous Close $3.95
Change ($) -0.10
Change (%) -2.53%
Day's Open 4.00
Day's Range 3.80 - 3.95
Day's Volume 25,656
52-Week Range 3.80 - 8.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BERWYN, Pa.--(BUSINESS WIRE)-- #licensing--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve a...

3 weeks ago - Business Wire

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced preclinical results of MMS019, its anti-viral product candidate for respiratory viruses. MMS019 is a high-density molecular masking spray the Comp...

3 weeks ago - Benzinga

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managemen...

3 weeks ago - Business Wire

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objectiv...

1 month ago - Benzinga

BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managem...

1 month ago - Accesswire

BERWYN, PA / ACCESSWIRE / March 22, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectab...

1 month ago - Accesswire

About VRPX

Virpax Pharmaceuticals is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. We are developing branded pharmaceutical product candidates for pain management by using advanced technology in an effort to enhance patients’ quality of life. We have exclusive global rights to develop, sell and export (among other rights) a proprietary patented nonsteroid anti-... [Read more...]

Industry
Biotechnology
IPO Date
Feb 17, 2021
CEO
Anthony Mack
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
VRPX
Full Company Profile

Financial Performance

Financial Statements